. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: J Cancer Surviv. 2014 Jan 4;8(2):260–268. doi: 10.1007/s11764-013-0337-z

Table 4.

Baseline and 12 month bone mineral density values by menopausal status in weight training and control groups.

Postmenopausal
	Weight training (n=111)			Control (n=114)

Regional BMD (g/cm²)	Baseline Mean (SD)	12 months Mean (SD)	% Change	Baseline Mean (SD)	12 months Mean (SD)	% Change	p-value^a

Spine (L₁–L₄)	0.987 (0.122)	0.981 (0.123)	−0.57	0.993 (0.149)	0.988 (0.149)	−0.54	0.80
Total hip	0.904 (0.113)	0.895 (0.117)	−1.05	0.894 (0.133)	0.884 (0.131)	−1.00	0.84
Greater trochanter	0.671 (0.091)	0.665 (0.095)	−0.87	0.662 (0.104)	0.655 (0.105)	−1.09	0.88
Femoral neck	0.761 (0.114)	0.745 (0.117)	−2.22	0.755 (0.119)	0.741 (0.111)	−1.72	0.40
Premenopausal
	Weight training (n=17)			Control (n=16)

Regional BMD (g/cm²)	Baseline Mean (SD)	12 months Mean (SD)	% Change	Baseline Mean (SD)	12 months Mean (SD)	% Change	p-value^a

Spine (L₁–L₄)	1.047 (0.147)	1.040 (0.154)	−0.69	1.028 (0.174)	1.025 (0.175)	−0.19	0.18
Total hip	0.969 (0.156)	0.968 (0.159)	−0.20	0.923 (0.124)	0.929 (0.134)	0.59	0.41
Greater trochanter	0.720 (0.133)	0.723 (0.136)	0.38	0.691 (0.102)	0.696 (0.105)	0.61	0.95
Femoral neck	0.843 (0.131)	0.827 (0.128)	−1.89	0.795 (0.101)	0.792 (0.102)	−0.34	0.17

p-value from mixed model for the time by group interaction that included baseline and 12-month time points and controlled for the following: age, time since diagnosis, current adjuvant hormone therapy use, baseline calcium intake, and current bisphosphonate use. p-values are observed and not corrected for multiple testing.